CJC-1295 & Ipamorelin Blend
A research blend combining CJC-1295 (no DAC / Mod GRF 1-29) with ipamorelin — the most commonly cited GHRH + GHS combination in GH secretagogue research.
Community Rating
No ratings yet
⚠ Research & Educational Use Only. CJC-1295 & Ipamorelin Blend is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Synergistic GH release via GHRHR + GHS-R1a
- Selective GH-axis action with minimal off-target effects
- Most studied GHRH + GHRP combination in research literature
- CJC-1295 & Ipamorelin Blend is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Synergistic GH release via GHRHR + GHS-R1a
- Selective GH-axis action with minimal off-target effects
- Most studied GHRH + GHRP combination in research literature
- Appropriate for long-term body composition research protocols
What is CJC-1295 & Ipamorelin Blend?
Tap any underlined term for an instant definition.
CJC-1295 & Ipamorelin Blend refers to the combination of CJC-1295 without DAC (identical to Mod GRF 1-29) with ipamorelin. This is the same combination discussed as "Mod GRF 1-29 + Ipamorelin" in the research literature, formulated under the more commercially recognizable CJC-1295 naming convention.
What It Is
- CJC-1295 (no DAC) = Mod GRF 1-29: the 4-substitution GHRH analogue without Drug Affinity Complex modification
- Ipamorelin: highly selective GHS-R1a agonist
- Identical mechanism and expected outcomes to Mod GRF 1-29 + Ipamorelin blend
- Note: distinct from CJC-1295 with DAC, which has 6-8 day half-life and produces sustained rather than pulsatile GH elevation
How It Works
- CJC-1295 (no DAC) provides GHRHR stimulation with ~30-60 minute half-life
- Ipamorelin provides complementary GHS-R1a stimulation and somatostatin suppression
- Synergistic GH pulses of 3-4x either peptide alone
- Physiological pulsatile GH pattern preserved
Key Research Findings
- Same evidence base as Mod GRF 1-29 + Ipamorelin
- Most widely used GH-stimulating peptide combination in the research community
- Strong safety profile from multiple long-term monitoring studies
Dosing From the Literature
- CJC-1295 (no DAC) 100-200 mcg + Ipamorelin 200-300 mcg per injection
- Twice daily on empty stomach
Storage and Handling
- Lyophilised: 2-8 degrees C; 24 months
- Reconstituted: 2-8 degrees C; use within 30 days
Key Research Benefits
Documented effects observed in preclinical and clinical studies on CJC-1295 & Ipamorelin Blend. See all Peptide Blends peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Subcutaneous injection on empty stomach. Twice daily: morning + bedtime.
Explore Further
Quick Reference
More in Peptide Blends
- Sermorelin & Ipamorelin Blend
- Sermorelin & GHRP-2 Blend
- Sermorelin & GHRP-6 Blend
- Sermorelin & GHRP-6 & GHRP-2 Triple Blend
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.